Roche's Tecentriq combination approved by FDA for adjuvant stage III DMMR colon cancer

Roche's Tecentriq combination was approved by the FDA for adjuvant treatment of stage III dMMR colon cancer, based on the ATOMIC trial showing 36-month disease-free survival of 86% versus 76% with chemotherapy alone.

Detected & updated continuously · Source: Nebula